WE‐E‐220‐07: Therapeutic Effects of Pulsed Focused Ultrasound Enhancement of Docetaxel Combined with Radiotherapy on Prostate Cancer In Vivo

L. Chen, Z. mu, X. Chen, D. Cvetkovic, Alan Pollack, C. ma

Research output: Contribution to journalArticle

Abstract

Purpose: We demonstrated a significant increase of 3H‐docetaxel in the prostate tumor treated with pulsed focused ultrasound (pFUS). This study is to study the efficacy of the increased uptake of docetaxel (doc) by pFUS in prostate tumor growth delay in vivo in combination with radiotherapy (RT). Methods: LNCaP cells were grown in the prostates of nude mice. The tumor growth was monitored by MRI. Pulsed FUS treatment was performed using an ExAblate 2000 system with 1.5 T GE MR Scanner. When the tumor volume reached 36 ± 5.9 mm3, mice were randomly divided into 7 groups (n=5): (1) pFUS only; (2) RT only; (3) doc only; (4) doc + pFUS; (5) doc + RT; (6) doc + pFUS + RT; and (7) control. Animals involved with pFUS were treated with 1 MHz; 5W acoustic power for 60 sec with 50% duty cycle per sonication. Animals treated with doc received a dose of 5 mg/kg by tail vein injection. The doc injection was performed before the pFUS and RT treatments. For the RT treatment, animals were irradiated on a Cesium 137 irradiator with a 2 Gy dose. Animals were allowed to survive for 4 weeks post‐treatment. Tumor volumes were measured by MRI at 1 and 4 weeks post‐treatment. Results: Results showed an average reduction in the tumor volume by 59% for animals treated with doc only; 37% with RT only; 54% with pFUS+doc; 65.8% with RT+doc, and 72% with pFUS + doc + RT, respectively, compared with that in the control group. Conclusions: Triple combination therapies of doc, pFUS and RT may have a potential for the treatment of prostate cancer. Due to the large variations in tumor growth between individual animals more experiments are needed for better statistics and to find optimal treatment doses, parameters and fractionation schemes.

Original languageEnglish (US)
Pages (from-to)3825
Number of pages1
JournalMedical Physics
Volume38
Issue number6
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

docetaxel
Therapeutic Uses
Prostatic Neoplasms
Radiotherapy
Tumor Burden
Prostate
Ultrasonic Waves
Neoplasms
Therapeutics
Growth
Dose Fractionation

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

WE‐E‐220‐07 : Therapeutic Effects of Pulsed Focused Ultrasound Enhancement of Docetaxel Combined with Radiotherapy on Prostate Cancer In Vivo. / Chen, L.; mu, Z.; Chen, X.; Cvetkovic, D.; Pollack, Alan; ma, C.

In: Medical Physics, Vol. 38, No. 6, 2011, p. 3825.

Research output: Contribution to journalArticle

@article{552b14bb915f42328cd0d7c98ad4930a,
title = "WE‐E‐220‐07: Therapeutic Effects of Pulsed Focused Ultrasound Enhancement of Docetaxel Combined with Radiotherapy on Prostate Cancer In Vivo",
abstract = "Purpose: We demonstrated a significant increase of 3H‐docetaxel in the prostate tumor treated with pulsed focused ultrasound (pFUS). This study is to study the efficacy of the increased uptake of docetaxel (doc) by pFUS in prostate tumor growth delay in vivo in combination with radiotherapy (RT). Methods: LNCaP cells were grown in the prostates of nude mice. The tumor growth was monitored by MRI. Pulsed FUS treatment was performed using an ExAblate 2000 system with 1.5 T GE MR Scanner. When the tumor volume reached 36 ± 5.9 mm3, mice were randomly divided into 7 groups (n=5): (1) pFUS only; (2) RT only; (3) doc only; (4) doc + pFUS; (5) doc + RT; (6) doc + pFUS + RT; and (7) control. Animals involved with pFUS were treated with 1 MHz; 5W acoustic power for 60 sec with 50{\%} duty cycle per sonication. Animals treated with doc received a dose of 5 mg/kg by tail vein injection. The doc injection was performed before the pFUS and RT treatments. For the RT treatment, animals were irradiated on a Cesium 137 irradiator with a 2 Gy dose. Animals were allowed to survive for 4 weeks post‐treatment. Tumor volumes were measured by MRI at 1 and 4 weeks post‐treatment. Results: Results showed an average reduction in the tumor volume by 59{\%} for animals treated with doc only; 37{\%} with RT only; 54{\%} with pFUS+doc; 65.8{\%} with RT+doc, and 72{\%} with pFUS + doc + RT, respectively, compared with that in the control group. Conclusions: Triple combination therapies of doc, pFUS and RT may have a potential for the treatment of prostate cancer. Due to the large variations in tumor growth between individual animals more experiments are needed for better statistics and to find optimal treatment doses, parameters and fractionation schemes.",
author = "L. Chen and Z. mu and X. Chen and D. Cvetkovic and Alan Pollack and C. ma",
year = "2011",
doi = "10.1118/1.3613402",
language = "English (US)",
volume = "38",
pages = "3825",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - WE‐E‐220‐07

T2 - Therapeutic Effects of Pulsed Focused Ultrasound Enhancement of Docetaxel Combined with Radiotherapy on Prostate Cancer In Vivo

AU - Chen, L.

AU - mu, Z.

AU - Chen, X.

AU - Cvetkovic, D.

AU - Pollack, Alan

AU - ma, C.

PY - 2011

Y1 - 2011

N2 - Purpose: We demonstrated a significant increase of 3H‐docetaxel in the prostate tumor treated with pulsed focused ultrasound (pFUS). This study is to study the efficacy of the increased uptake of docetaxel (doc) by pFUS in prostate tumor growth delay in vivo in combination with radiotherapy (RT). Methods: LNCaP cells were grown in the prostates of nude mice. The tumor growth was monitored by MRI. Pulsed FUS treatment was performed using an ExAblate 2000 system with 1.5 T GE MR Scanner. When the tumor volume reached 36 ± 5.9 mm3, mice were randomly divided into 7 groups (n=5): (1) pFUS only; (2) RT only; (3) doc only; (4) doc + pFUS; (5) doc + RT; (6) doc + pFUS + RT; and (7) control. Animals involved with pFUS were treated with 1 MHz; 5W acoustic power for 60 sec with 50% duty cycle per sonication. Animals treated with doc received a dose of 5 mg/kg by tail vein injection. The doc injection was performed before the pFUS and RT treatments. For the RT treatment, animals were irradiated on a Cesium 137 irradiator with a 2 Gy dose. Animals were allowed to survive for 4 weeks post‐treatment. Tumor volumes were measured by MRI at 1 and 4 weeks post‐treatment. Results: Results showed an average reduction in the tumor volume by 59% for animals treated with doc only; 37% with RT only; 54% with pFUS+doc; 65.8% with RT+doc, and 72% with pFUS + doc + RT, respectively, compared with that in the control group. Conclusions: Triple combination therapies of doc, pFUS and RT may have a potential for the treatment of prostate cancer. Due to the large variations in tumor growth between individual animals more experiments are needed for better statistics and to find optimal treatment doses, parameters and fractionation schemes.

AB - Purpose: We demonstrated a significant increase of 3H‐docetaxel in the prostate tumor treated with pulsed focused ultrasound (pFUS). This study is to study the efficacy of the increased uptake of docetaxel (doc) by pFUS in prostate tumor growth delay in vivo in combination with radiotherapy (RT). Methods: LNCaP cells were grown in the prostates of nude mice. The tumor growth was monitored by MRI. Pulsed FUS treatment was performed using an ExAblate 2000 system with 1.5 T GE MR Scanner. When the tumor volume reached 36 ± 5.9 mm3, mice were randomly divided into 7 groups (n=5): (1) pFUS only; (2) RT only; (3) doc only; (4) doc + pFUS; (5) doc + RT; (6) doc + pFUS + RT; and (7) control. Animals involved with pFUS were treated with 1 MHz; 5W acoustic power for 60 sec with 50% duty cycle per sonication. Animals treated with doc received a dose of 5 mg/kg by tail vein injection. The doc injection was performed before the pFUS and RT treatments. For the RT treatment, animals were irradiated on a Cesium 137 irradiator with a 2 Gy dose. Animals were allowed to survive for 4 weeks post‐treatment. Tumor volumes were measured by MRI at 1 and 4 weeks post‐treatment. Results: Results showed an average reduction in the tumor volume by 59% for animals treated with doc only; 37% with RT only; 54% with pFUS+doc; 65.8% with RT+doc, and 72% with pFUS + doc + RT, respectively, compared with that in the control group. Conclusions: Triple combination therapies of doc, pFUS and RT may have a potential for the treatment of prostate cancer. Due to the large variations in tumor growth between individual animals more experiments are needed for better statistics and to find optimal treatment doses, parameters and fractionation schemes.

UR - http://www.scopus.com/inward/record.url?scp=85024776786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024776786&partnerID=8YFLogxK

U2 - 10.1118/1.3613402

DO - 10.1118/1.3613402

M3 - Article

AN - SCOPUS:85024776786

VL - 38

SP - 3825

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -